Literature DB >> 1964676

Phase II study of carbetimer in non-small cell lung cancer.

M Keaton1, T Brown, J Craig, G Fries, G Harmon, A Zaloznik, G Orczyk, D Von Hoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1964676     DOI： 10.1007/bf00198596

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  4 in total

1.  Phase I trial of the polyelectrolyte carbetimer administered i.v. once every four weeks.

Authors:  M Fromm; W E Berdel; H D Schick; S Danhauser-Riedl; U Fink; W Remy; A Reichert; A Ankele; H W Präuer; J R Siewert
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

2.  Phase I clinical trial of carbetimer.

Authors:  A R Hanauske; T J Melink; G S Harman; G M Clark; J B Craig; J M Koeller; D H Boldt; B Kantor; D L Kisner; G Orczyk
Journal:  Cancer Res       Date:  1988-09-15       Impact factor: 12.701

3.  Activity of Carbetimer in a human tumor cloning system.

Authors:  D L Kisner; P Mehta; G E Paget; D D Von Hoff
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  Carboxyimamidate, a low-molecular-weight polyelectrolyte with antitumor properties and low toxicity.

Authors:  J E Fields; S S Asculai; J H Johnson; R K Johnson
Journal:  J Med Chem       Date:  1982-09       Impact factor: 7.446
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.